Emmaus Life Sciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Willis C. Lee
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21250 Hawthorne Boulevard Torrance CA United States of America 90503
- IPO Date
- May 9, 2000
- CIK
- 0000822370
- Website
- emmausmedical.com
- Similar Companies
- Business
- Emmaus Life Sciences, Inc. (EMMA) is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies for rare and orphan diseases, with a primary focus on sickle cell disease. The company markets Endari (L-glutamine oral powder), approved by the U.S. Food and Drug Administration to reduce acute complications of sickle cell disease in adult and pediatric patients five years and older; its pipeline includes ELS004, a pharmaceutical-grade L-glutamine in Phase 1 clinical trials for diverticulosis, ELS005 for blood cancers, ELS003 as a lab device to measure transmittance of cell sheets, and ELS002 as a chondrocyte cell sheet technology for knee cartilage replacement or osteoarthritis treatment. Endari receives marketing approval in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman, and is available on a named-patient or early access basis in France, the Netherlands and the Kingdom of Saudi Arabia, where the company recently received market exclusivity and awaits final marketing authorization. Founded in 2000 and headquartered in Torrance, California, Emmaus Life Sciences operates in the biotechnology sector, targeting patients with sickle cell disease and other rare conditions primarily in the U.S. and Middle East North Africa region. Recent developments include the appointment of Willis C. Lee as chief executive officer in July 2024 to enhance operational efficiency and pursue Middle East expansion amid generic L-glutamine competition; FDA approval for Endari label enhancements in June 2025; and a grant of market exclusivity for Endari in Saudi Arabia in January 2025.
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Reports Annual Financial Results
Emmaus Life Sciences Announces Strategic Transaction
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Reports Improved Quarterly Financial Results
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
Emmaus Life Sciences Reports 2023 Financial Results
Emmaus Life Sciences Reports Delayed Filing of Annual Report
Emmaus Life Sciences obtains marketing authorization for sickle cell disease teatment in Puerto Rico
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
Emmaus Life Sciences sees increased Endari sales in MENA and US during 3Q
Emmaus Life Sciences Reports Q3 2023 Financial Results
Emmaus Life Sciences to focus on boosting sales of its sickle cell disease treatment Endari amid leadership transition
Emmaus Life Sciences Reports Management Changes